Tesamorelin Side Effects: What the Label Says

Whose side effects the label describes

Tesamorelin is approved for one use: reducing excess abdominal fat in adults with HIV who have lipodystrophy. Its side-effect data come from that population. The EGRIFTA WR label counts 740 adults with HIV, lipodystrophy and excess abdominal fat treated in the clinical trials, 543 of whom received tesamorelin during the 26-week placebo-controlled phase, against 263 on placebo ^[1].

The trials were selective. They enrolled adults aged 18 to 65 with a large waist and waist-to-hip ratio, and excluded people with type 1 or type 2 diabetes, anyone on insulin or diabetes tablets, anyone with a history of cancer, and anyone with hypopituitarism ^[1]. Those exclusions matter when reading the tables below, because the people most likely to be harmed by a rise in glucose or growth factors were kept out.

The current formulation was not tested separately. The label states that the safety of EGRIFTA WR rests on the trials of the original EGRIFTA formulation, and that its adverse reactions are expected to be similar ^[1]. The label was revised in March 2025 and was listed on DailyMed in September 2026.

Adverse reactions in the trials

The label lists every adverse reaction reported in at least 1 percent of treated patients during the first 26 weeks, and more often than with placebo ^[1]. Injection site reactions lead the list, followed by joint pain. Joint pain, extremity pain, peripheral swelling and carpal tunnel syndrome are what the label calls edema-related reactions, the fluid-retention effects that follow from raising growth hormone ^[1].

Injection site reactions appear twice in the label with different figures. The table's grouped entry gives 17 percent against 6 percent with placebo; the warnings section, describing injection site reactions over the same 26 weeks, gives 25 percent against 14 percent ^[1]. Both are reproduced here as printed.

Warnings and precautions

The warnings follow from what the drug does. Tesamorelin makes the pituitary release more growth hormone, which raises IGF-1, a growth factor, and growth hormone also retains fluid and opposes insulin. Each of those effects has its own warning, and the label gives measured figures for most of them ^[1].

Antibodies are common. Anti-tesamorelin antibodies were detected in 50 percent of patients after 26 weeks and in 85 percent of those who had a hypersensitivity reaction; about 60 percent of antibody-positive patients showed cross-reactivity with the body's own growth hormone-releasing hormone. Patients with and without antibodies had similar reductions in abdominal fat ^[1].

Who should not take it

The label lists four contraindications: disruption of the hypothalamic-pituitary axis from hypophysectomy, hypopituitarism, a pituitary tumor or surgery, head irradiation or head trauma; active malignancy; known hypersensitivity to tesamorelin or its excipients; and pregnancy ^[1]. The pregnancy contraindication rests on animal data: tesamorelin given to pregnant rats produced hydrocephaly in their offspring ^[1].

The label also records what it does not know. Safety and effectiveness in children have not been established, and in children whose growth plates are open it may cause excessive growth. There is no information on patients older than 65, and long-term cardiovascular safety has not been established ^[1].

What the trials measured before and after

The trials measured visceral fat, the fat around the organs, by CT scan at the level of the lower spine. After 26 weeks it fell by an average of 27 square centimeters in the first study and 21 in the second, while it rose by 4 or did not change with placebo; in percentage terms, falls of 18 and 14 percent against a rise of 2 and a fall of 2 ^[1]. The pooled analysis of 806 patients found a treatment effect of 15.4 percent, with no significant change in the fat under the skin ^[3].

Body weight did not move. The label's own table shows weight changes of less than one kilogram in either direction, and it states that tesamorelin is not indicated for weight loss because its effect on weight is neutral ^[1]. Waist circumference fell by 2 to 3 centimeters against about 1 with placebo ^[1].

The effect lasts only while treatment continues. Patients who stayed on tesamorelin for a year kept a reduction of about 18 percent ^{[2, 4]}; those switched to placebo at 26 weeks regained visceral fat, by 25 and 24 square centimeters in the two extension phases, and the reduction was lost ^{[1, 4]}.

Why there is no compounded version

Every figure above describes the licensed product. Tesamorelin has 44 amino acids, and the FDA defines any chain of more than 40 as a protein ^[8], so on March 23, 2020 its application was deemed a biologics license ^{[5, 6]}. Biological products that made that transition are not eligible for the compounding exemptions in sections 503A and 503B ^[7]. There is no lawful compounded tesamorelin, and no compounded product carries this label or was tested in these trials.

Use outside HIV lipodystrophy falls outside the label altogether. The small trials in other populations are reviewed in tesamorelin off-label, and the comparison with the compounded GHRH analog sermorelin is set out in sermorelin vs tesamorelin. The drug's place in its class is on the GH secretagogues page, and its legal position on the approved status page.

Elsewhere in this index